Praxis precision medicines to present at two february investor conferences

Boston, feb. 03, 2025 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:
PRAX Ratings Summary
PRAX Quant Ranking